Bone Biologics completed a US $5.75MM funding round with participation from Musculoskeletal Transplant Foundation, Orthofix and Hankey Capital. Proceeds will support development and synthesis of a potential bone graft substitute, with an initial focus on spinal fusion applications.
Bone Biologics developed Nell-1™ bone growth factor as a lower-cost alternative to current growth factor products.
In late 2Q15, Biologics completed a $2MM funding round intended to support preparation for human clinical trials to validate the technology.
Bone Biologics completed a US $5.75MM funding round with participation from Musculoskeletal Transplant Foundation, Orthofix and Hankey Capital. Proceeds will support development and synthesis of a potential bone graft substitute, with an initial focus on spinal fusion applications.
Bone Biologics completed a US $5.75MM funding round with participation from Musculoskeletal Transplant Foundation, Orthofix and Hankey Capital. Proceeds will support development and synthesis of a potential bone graft substitute, with an initial focus on spinal fusion applications.
Copy to clipboard 
